Cerenome, Inc.

Cerenome, Inc.

3.28
EUR
+0.12
(+3.63%)
-4.20EPS
24.86MMarket Cap

Total Valuation

EUR

As of June 30, 2026, Cerenome, Inc. carries a market capitalization of 24.86M, placing it among publicly traded companies globally. Its enterprise value stands at 17.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap24.86M
Enterprise Value17.38M

Important Dates

Cerenome, Inc.'s next confirmed earnings release is scheduled for October 22, 2026.

Earnings Date10/22/2026

Share Statistics

As of June 30, 2026, Cerenome, Inc. has 6.63M shares outstanding.

Shares Outstanding6.63M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio5.20
P/TBV Ratio5.89
P/FCF Ratio-0.99
P/OCF Ratio-1.05

Financial Position

As of June 30, 2026, Cerenome, Inc. maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.81, indicating moderate leverage, while an interest coverage ratio of -8.42 demonstrates limited ability to service its debt obligations.

Current Ratio1.37
Quick Ratio1.23
Debt / Equity0.81
Interest Coverage-8.42

Financial Efficiency

Over the twelve months ended June 30, 2026, Cerenome, Inc. posted a negative return on equity (ROE) of -614.05, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -214.01, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 26.25, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-614.05
Return on Assets (ROA)-214.01
Employee Count26.25

Stock Price Statistics

EUR

These figures are as of the close on July 31, 2026.

50-Day Moving Average3.99

Income Statement

EUR

Over the twelve months ended June 30, 2026, Cerenome, Inc. generated - - in revenue and converted that into -22.83M in net income, yielding earnings per share of -4.20. EBITDA reached -22.71M, while operating income came in at -23.11M.

Operating Income-23.11M
Pretax Income-22.83M
Net Income-22.83M
EBITDA-22.71M
EBIT-23.11M
Earnings Per Share (EPS)-4.20

Balance Sheet

EUR

As of June 30, 2026, Cerenome, Inc. holds 7.52M in cash and equivalents against 38,513.20 in total debt, resulting in a net debt position of -2.07M. Total book value stands at 4.78M, with working capital of 2.80M providing operational flexibility.

Cash & Cash Equivalents7.52M
Total Debt38,513.20
Net Debt-2.07M
Equity (Book Value)4.78M
Book Value Per Share0.72
Working Capital2.80M

Cash Flow

EUR

Cerenome, Inc. produced -19.41M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.20M in capital expenditures, free cash flow totaled -20.61M - equivalent to -3.79 per share.

Operating Cash Flow-19.41M
Capital Expenditures-1.20M
Free Cash Flow-20.61M
FCF Per Share-3.79

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -101.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -88.92, meaning Cerenome, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-88.92
FCF Yield-101.19

Stock Splits

Cerenome, Inc.'s most recent stock split took place on April 2, 2026 with a 25:1 split ratio.

Last Split Date4/2/2026
Split Ratio25:1

Scores

As of June 30, 2026, Cerenome, Inc. has an Altman Z-Score of -59.82, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-59.82